|
|
|
|
| LEADER |
01620 am a22001933u 4500 |
| 001 |
40878 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Hanafiah, Khayriyyah Mohd
|e author
|
| 700 |
1 |
0 |
|a Arifin, Norsyahida
|e author
|
| 700 |
1 |
0 |
|a Bustami, Yazmin
|e author
|
| 700 |
1 |
0 |
|a Noordin, Rahmah
|e author
|
| 700 |
1 |
0 |
|a Garcia, Mary
|e author
|
| 700 |
1 |
0 |
|a Anderson, David
|e author
|
| 245 |
0 |
0 |
|a Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities
|
| 260 |
|
|
|b MDPI,
|c 2017.
|
| 856 |
|
|
|z Get fulltext
|u http://eprints.usm.my/40878/1/Development_of_Multiplexed_Infectious_Disease_Late.pdf
|
| 520 |
|
|
|a Lateral flow assays (LFAs) are the mainstay of rapid point-of-care diagnostics, with the potential to enable early case management and transform the epidemiology of infectious disease. However, most LFAs only detect single biomarkers. Recognizing the complex nature of human disease, overlapping symptoms and states of co-infections, there is increasing demand for multiplexed systems that can detect multiple biomarkers simultaneously. Due to innate limitations in the design of traditional membrane-based LFAs, multiplexing is arguably limited to a small number of biomarkers. Here, we summarize the need for multiplexed LFA, key technical and operational challenges for multiplexing, inherent in the design and production of multiplexed LFAs, as well as emerging enabling technologies that may be able to address these challenges. We further identify important areas for research in efforts towards developing multiplexed LFAs for more impactful diagnosis of infectious diseases.
|
| 546 |
|
|
|a en
|
| 650 |
0 |
4 |
|a QH301 Biology
|
